ArticleFrontiers in medicine2026
Case Report: Influenza B-triggered CIDP revealing PMP22-related Dejerine-Sottas-like neuropathy in a child-biphasic cytokine dynamics and response to immunotherapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dejerine-Sottas disease (DSD) is a severe early-onset hereditary demyelinating neuropathy, but its overlap with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has rarely been described in children. We report a child in whom influenza B-triggered CIDP led to the recognition of a previously undiagnosed PMP22-related hereditary demyelinating neuropathy with a severe Dejerine-Sottas-like phenotype. The patient had longstanding developmental delay and neuropathic features before the acute illness. After severe influenza B infection, he developed progressive weakness lasting more than 8 weeks, marked albuminocytologic dissociation, biphasic cytokine elevation in serum and cerebrospinal fluid (CSF), diffuse peripheral nerve enlargement, and electrophysiological evidence of diffuse, largely symmetric sensorimotor polyneuropathy with prominent demyelinating features and secondary axonal involvement. Genetic testing identified a maternally inherited heterozygous 1.38-Mb deletion at chromosome 17p12 involving the dosage-sensitive PMP22 gene. Treatment with intravenous immunoglobulin and corticosteroids was followed by improvements consciousness, respiratory function, limb strength, and cytokine levels, although motor recovery remained incomplete. In children with features of hereditary neuropathy, acute or subacute deterioration after infection should prompt evaluation for superimposed CIDP, as the inflammatory component may be responsive to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.